In a secondary analysis of the LOCATE and FALCON prospective clinical trials, researchers from the Washington University School of Medicine reported that Axumin PET/CT detected lesions in 85 (58%) of the 146 patients who had received a prescan plan for androgen deprivation therapy, according to Blue Earth. Of the 146, 93 (64%) had a change in their management plan following the exam.
Androgen deprivation therapy was avoided or delayed in 55 (59%) of the 93 patients whose management plan had changed. In addition, only 15 (25%) of the 60 patients originally planned for androgen deprivation therapy monotherapy were still due to receive that treatment plan after Axumin PET/CT imaging, according to Blue Earth.
The results were presented on September 23 at the Global Summit on Precision Diagnosis and Treatment of Prostate Cancer.
Copyright © 2021 AuntMinnie.com